6/17/2023 0 Comments Emulsion de scott![]() ![]() Patients with end stage renal disease may develop hypercalcemia when treated with Emulsion de Scott (Calcium Phosphate), including Emulsion de Scott (Calcium Phosphate) acetate. Hypercalcemia may aggravate digitalis toxicity. Severe hypercalcemia may require hemodialysis and discontinuation of Emulsion de Scott (Calcium Phosphate) acetate. Treat mild hypercalcemia by reducing or interrupting Emulsion de Scott acetate and Vitamin D. Capsule: 667 mg Emulsion de Scott (Calcium Phosphate) acetate capsule. ![]() (2)Ĭapsule: 667 mg Emulsion de Scott (Calcium Phosphate) acetate capsule. Most patients require 3 to 4 capsules with each meal. Titrate the dose every 2 to 3 weeks until acceptable serum phosphorus level is reached. Starting dose is 2 capsules with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. The recommended initial dose of Emulsion de Scott (Calcium Phosphate) acetate for the adult dialysis patient is 2 capsules with each meal. Calcium acetate is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease. Emulsion de Scott (Calcium Phosphate) acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). ![]()
0 Comments
Leave a Reply. |